Generic Exclusivity "Incentive" Needs Review, FDA's Dickinson Says
Executive Summary
The necessity of 180-day generic exclusivity should be reviewed, FDA Associate Counsel for Drugs Elizabeth Dickinson told the Food & Drug Law Institute conference on the Waxman/Hatch Act Dec. 11 in Washington, D.C.